This technology utilizes ferulic acid, a natural phenolic acid, or its salts as an active ingredient to prevent and treat skin diseases caused by genetic mutations, such as epidermolysis bullosa. The same ingredient can be applied in the form of pharmaceuticals, cosmetics, and health functional foods.
Keratin-related genetic skin diseases like epidermolysis bullosa, which cause severe blistering from minor trauma due to weak adhesion between the epidermis and dermis, currently have no cure. While treatments like steroid prescriptions and bone marrow transplants have been studied, they have been limited to symptomatic relief focused on infection prevention and pain management.
This technology addresses the root cause of the disease by leveraging the ability of ferulic acid to increase keratin 6A protein expression and differentially regulate beta-catenin expression in the epidermis and dermis. Applicable to treatments for rare genetic skin diseases, functional cosmetics for skin barrier improvement, and health functional foods, it offers a management solution beyond symptomatic treatment using a safe, plant-derived ingredient.
US2023-0285336A1, WO2021-107381A1
